Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion type Assertion NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_head.
- NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion description "[First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_provenance.
- NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion evidence source_evidence_literature NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_provenance.
- NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion SIO_000772 22215754 NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_provenance.
- NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion wasDerivedFrom befree-20140225 NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_provenance.
- NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_assertion wasGeneratedBy ECO_0000203 NP904317.RAGS9F6dC5KTtEYg0lu1gy4GHEjJ8xh0_PGdNlcY8xSe8130_provenance.